ECM Rejuvenation and Crosslink Breakers

The Role of the Extracellular Matrix in Ageing

Biological ageing affects not only cells themselves but also the extracellular matrix (ECM), the structural network composed of collagen, elastin, proteoglycans, and glycoproteins. With age and metabolic stress, the composition and mechanical properties of the ECM can change. In many tissues it becomes stiffer, less organized, and more crosslinked.

Cells sense matrix stiffness through mechanotransduction pathways. A stiffer ECM can alter cell behaviour, inflammatory signalling, and repair responses. This makes ECM ageing relevant to tissue function, but it does not mean that reversing one crosslink type would automatically reverse tissue ageing.

Advanced Glycation End-products and Glucosepane

Non-enzymatic glycation is one contributor to age-related ECM stiffening. Other tissue-dependent contributors include altered matrix synthesis and degradation, enzymatic crosslinking, collagen accumulation, elastin fragmentation, calcification, and oxidative modification. Sugars and sugar-derived molecules can react with long-lived matrix proteins and eventually form heterogeneous Advanced Glycation End-products (AGEs). [3] [4]

In humans, glucosepane is an abundant AGE crosslink in long-lived extracellular proteins. Because collagen and elastin turn over slowly in some tissues, these modifications can accumulate over time. Crosslinking can reduce tissue elasticity in vascular walls, kidneys, lung tissue, and skin, and arterial stiffness is one pathway linked to systolic hypertension and cardiovascular risk.

Crosslink Breakers: A History of Iteration

Therapeutics designed to pharmacologically cleave AGEs are termed "crosslink breakers" or AGE breakers. This is fundamentally a structural chemistry problem.

• Alagebrium: Alagebrium (ALT-711) was studied as an AGE breaker and showed some early signals related to arterial stiffness, but development did not establish an approved therapy for age-related ECM crosslinking. It also did not solve the central glucosepane-cleavage problem.
• More specific cleavage strategies: Current research explores enzymes, catalysts, and other approaches designed to target specific crosslink chemistry. The challenge is to cleave relevant bonds in dense tissue without damaging host proteins or producing harmful downstream products.

What a Successful Reversal Study Would Need to Show

A convincing intervention must do more than lower a circulating AGE marker. It should identify the chemical bond being targeted, demonstrate that the agent reaches the relevant matrix compartment, and directly measure loss of that crosslink in tissue. Because glucosepane has complex chemistry and lacks a simple natural cleavage pathway, access to well-characterized synthetic material and selective analytical methods is important for testing candidate binders or catalysts. [2]

Mechanical and functional outcomes must then agree with the biochemical result. Depending on the tissue, these might include arterial compliance, renal filtration, lung elasticity, skin mechanics, or mobility. A change in stiffness is not automatically evidence of glucosepane cleavage: collagen turnover, hydration, enzymatic crosslinking, calcification, inflammation, and blood pressure can also change tissue mechanics. Studies therefore need appropriate controls and should separate prevention of new AGE formation from cleavage of crosslinks that are already present.

Tissue context matters as well. AGE composition, protein turnover, and exposure to glucose or oxidative stress differ between skin, arteries, cartilage, kidney, and other organs. A compound active in a simplified chemical system may be unstable, nonspecific, or unable to penetrate intact human tissue. Translation requires evidence at each of these levels rather than inference from a single assay.

Status of ECM Translational Therapy

Confidence is strong that ECM stiffening and glycation are relevant to ageing biology and cardiometabolic disease. Confidence is much lower that current crosslink-breaking strategies can safely and meaningfully reverse established tissue ageing in humans. The strongest interpretation is mechanistic plausibility with substantial chemistry, delivery, and clinical-validation barriers.

References

1. Monnier, V. M. et al. "Skin Collagen Advanced Glycation End Products (AGEs) and the Diabetic Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort." Diabetes (2018). https://doi.org/10.2337/db18-0520
2. Draghici, C. et al. "Concise total synthesis of glucosepane." Science (2015). https://doi.org/10.1126/science.aac9655
3. Birch, H. L. "Extracellular Matrix and Ageing." Subcellular Biochemistry (2018), 90, 169-190. https://pubmed.ncbi.nlm.nih.gov/30779010/
4. Heinz, A. "Elastic fibers during aging and disease." Ageing Research Reviews (2021), 66, 101255. https://pubmed.ncbi.nlm.nih.gov/33434682/